Baird’s AstraZeneca AZN Stock Holding History

Baird’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$1.78M	Buy	26,052 +507	+2%	+$35.2K	0.02%	574
2014 Q4	$1.8M	Buy	25,545 +2,042	+9%	+$146K	0.02%	568
2014 Q3	$1.68M	Buy	23,503 +351	+2%	+$25.7K	0.02%	506
2014 Q2	$1.72M	Sell	23,152 -35,241	-60%	-$2.55M	0.02%	522
2014 Q1	$3.79M	Buy	58,393 +33,775	+137%	+$2.18M	0.05%	329
2013 Q4	$1.46M	Sell	24,618 -269	-1%	-$14.6K	0.03%	519
2013 Q3	$1.29M	Sell	24,887 -8,870	-26%	-$446K	0.02%	523
2013 Q2	$1.6M	Buy	+33,757	New	+$1.72M	0.03%	461

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Baird's AZN Position: Q1 2015 in Review

Baird increased its AstraZeneca (AZN) stake by 2% in Q1 2015, buying an estimated $35.2K and bringing the position to 26,052 shares worth $1.78M. The position accounts for 0.02% of the portfolio, ranked #574.

Baird first reported a position in AZN in Q2 2013 and has held it in 8 quarters since. The position peaked at $3.79M in Q1 2014. 386 funds tracked by Wall St. Rank hold AZN as of Q1 2015.

Baird held 26,052 shares of AstraZeneca worth $1.78M as of Q1 2015.
Baird bought 507 AstraZeneca shares in Q1 2015, an estimated $35.2K.
AstraZeneca made up 0.02% of Baird's portfolio in Q1 2015, its #574 holding.
Baird first reported a position in AstraZeneca in Q2 2013 and has held it in 8 quarters since.
Baird's AstraZeneca position peaked at $3.79M in Q1 2014.
386 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.